ClinicalTrials.gg
RecruitingNCT07613385Updated Oct 6, 2026

Individualized AML Treatment

An observational study in Relapsed/Refractory Acute Myeloid Leukemia (AML), sponsored by City of Hope Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by City of Hope Medical Center · Observational

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.
Updated Oct 6, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
20
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 63 studies in Leukemia, Myeloid, Acute by City of Hope Medical Center — 15 open to participants now, 32 under way, none of them phase 3. Leukemia, Myeloid, Acute · City of Hope Medical Center.

Started
2026
with 4 others
Observational
6 of 63
1 open now
Primary completion
2028-06
later than 24 of 31 live
Registered
63rd of 63
by date

Among the 63 studies in Leukemia, Myeloid, Acute by City of Hope Medical Center, this one is one of 5 that started in 2026, is one of 6 observational ones, reaches primary completion later than 24 of the 31 other live ones, and was the 63rd registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

15 of the 63 studies in Leukemia, Myeloid, Acute by City of Hope Medical Center are open now, in 1 country. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Where they have run

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies in Leukemia, Myeloid, Acute by City of Hope Medical Center, or all of them as a file.
02

Study summary

Every patient responds differently to their cancer treatment, and some treatments work better for some patients more than others. For patients with relapsed, refractory ( R/R) AML, there may be fewer approved treatment options remaining. In this research study, the investigators are testing whether high throughput drug screening (HTS) in combination with robust molecular testing by HopeSeq (includes DNA sequencing for >500 genes and 160 gene rearrangements and RNAseq for >5,000 genes) can help doctors determine which treatment might work best for each individual patient. HTS tests how the patient's own AML cells respond to different treatment options including individual drugs and triple drug regimens and recommends for the best treatment options for an individual patient. Participants will provide extra bone marrow and/or blood at the time of routine procedure, and these extra sample(s) will be tested using the Cancer Drug Sensitivity Test ( CDST) HTS, CLIA approved in Washington state since 2014. A committee (the Functional Molecular Tumor Board) will review the HopeSeq and HTS results, past treatments, and clinical description, and give a recommendation for the best AML treatment options for each individual patient. The patient's doctor will get a copy of the recommendation and discuss treatment options with the patient. The patient and their doctor will decide on the best treatment plan for the patient, one which will be approved by insurance. Patients will not be treated with any drugs as part of this study. Then at 6 and 12 months, there will be retrospective review of medical records to determine how will the testing predicted the response, drug sensitivity or resistance, and overall and disease-free survival will be monitored.

Read the detailed description

The investigators will utilize high throughput drug screening (HTS) to assess sensitivity of patient's leukemic cells to drugs and drug combinations (\~135). Bone marrow aspirate (BMA) or peripheral blood blasts, or if these are not involved, then bone marrow or tissue biopsy or involved fluids will be used for testing in the HTS and time to HTS report will be recorded. Genomics analysis (sequencing) will be utilized to additionally inform drug choice using the City of Hope HopeSeq Heme Comprehensive (HopeSeq) targeted next generation sequencing (NGS) and RNA seq assays. The turnaround time (TAT) of the above NGS assays is 8-10 business days (≈12-14 calendar days). The Cancer Drug Sensitivity Test Diagnostic (CDST) is a HTS assay with a faster TAT (5-7 calendar days) that is CLIA-approved for patient diagnostic purposes. CDST HTS will be performed in the Quellos High Throughput Core Facility at the University of Washington (UW) in Seattle, WA. These assays detect relevant genomic, and transcriptomic, and functional data events which the investigators hypothesize will provide an opportunity to rationally tailor drug selections and combinations for the treatment of patients with AML that have relapsed and/or refractory AML. HopeSeq, which includes most of the relevant genomic pathways in hematologic malignancies, will be performed on peripheral blood (PB) or bone marrow aspirate (BMA), or if insufficient cells, formalin fixed paraffin embedded (FFPE) tissues may also be analyzed. HopeSeq will be performed as conventional care \~14 days prior to, or at the time of study enrollment, or study will access the results through the Hematopoietic Tissue Biorepository (HTB) at City of Hope. Based on the molecular diagnosis report from HopeSeq and the CDST HTS report, the investigators A propose to convene a Functional Molecular Tumor Board (FMTB) will meet that will consider the data from the molecular and functional studies, as well as information from a literature review for clinical and laboratory findings for other patients with the specific clinical features and molecular/functional data that will offer patients and their physicians treatment recommendations possible treatment options based on multiomic data (HopeSeq and CDST HTS reports) as well as clinical features within 14-18 days from sample acquisition.

But ultimately, the patient's treating physician will decide which regimen is best considering individual patient factors such as performance status, prior regimens, insurance authorization, and patient preferences. The retrospective correlation with patient response will enable determination of the relative predictive contribution of each of the tests, both positive and negative predictive value.

03

Conditions studied

  • Relapsed/Refractory Acute Myeloid Leukemia (AML)

Keywords

  • Feasibility study
  • Acute myeloid leukemia
  • Individualized treatment
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults with relapsed/refractory acute myeloid leukemia

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented of the participant and/or legally authorized representative.
  • Agreement to allow the use of from diagnostic tumor biopsies
  • Age: ≥ 18 years
  • ≤ 3 (Appendix A)
  • Patients with confirmed AML according to ICC or WHO criteria, and
  • /relapsed (R/R) to prior treatment with one or more regimens if adverse risk or two or more regimens if favorable/intermediate risk (Appendix B)
  • Sufficient bone marrow and/or peripheral blood sample (archival or fresh) to run the high throughput screening (HTS; Estimate sufficient if circulating blast count of 5,000 or greater or cellular marrow with greater than or equal to 20% blasts.) Otherwise,
  • Sufficient cells flushed from bone marrow biopsy, if bone marrow is not aspirable, OR
  • Extramedullary disease, if it is possible to obtain a fluid or biopsy sample from that location
  • Expected survival is greater than 100 days.
  • Fully recovered from the acute toxic effects (except alopecia) to ≤ Grade 1 to prior anti-cancer therapy

Exclusion criteria

Exclusion Criteria:

  • Treatment with any chemotherapeutic agent necessary to control AML burden is permitted between day -18 and -1.
  • Must not have received or planning to receive while being on study
  • Patients with t(15;17) karyotypic abnormality or acute promyelocytic leukemia (FAB class M3-AML)
  • Active central nervous system (CNS) disease (OK if treated and responding)
  • Active graft vs host disease ()
  • Unstable cardiac disease as defined by one of the following:
  • Cardiac events such as myocardial infarction (MI) within the past 6 months
  • Uncontrolled atrial fibrillation or hypertension
  • uncontrolled illness
  • Uncontrolled active infection
  • Females only: Pregnant or breastfeeding
  • Any other condition or active that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures.
  • Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics).
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
20 participants (estimated)
Patient registry
No

Groups and cohorts

  • R/R AML

    Adults with relapsed/refractory acute myeloid leukemia

    Other: Observational

Interventions

  • OtherObservational

    This is a non-interventional study

06

What researchers measure

Primary outcomes

  1. Feasibility - Obtaining HopeSeq and CDST

    Success in obtaining HopeSeq Heme Comprehensive (HopeSeq) and Cancer Drug Sensitivity Test Diagnostic (CDST) High Throughput Screen (HTS) reports and interpretation of results by the Functional Molecular Tumor Board (FMTB) Success of performing HOPESEQ and CDST HTS and obtaining an individualized treatment recommendation from the FMTB based on multiomic data within 18 days from sample acquisition.

    Time frame: Up to 18 days after sample acquisition

Secondary outcomes

  1. Proportion of participants with successful CDST HTS reports

    Samples received with sufficient cell numbers and viability to perform CDST HTS Success of performing HOPESEQ and CDST HTS and obtaining an individualized treatment recommendation from the FMTB based on multiomic data within 18 days from sample acquisition in at least 70% of participants.

    Time frame: Up to 18 days of sample acquisition

  2. Proportion of patients with successful initiation of treatment

    Successful initiation of treatment

    Time frame: Up to 1 year

  3. Average time to successful initiation of treatment

    Time from sample acquisition to successful initiation of treatment

    Time frame: Up to 1 year

  4. Degree of cytoreduction

    Bone marrow percent cellularity and percent leukemia by morphology and flow cytometry compared to pre-treatment level

    Time frame: Up to 2-5 weeks after treatment

  5. Preliminary estimate of remission

    Response, duration of remission, time to next treatment as compared to prior interval with most recent treatment, ability to proceed to transplant Using AML Risk Stratification Criteria by Genetics at Initial Diagnosis from Dohner et al. (2022)

    Time frame: Up to 1 year

  6. Overall survival (OS) and progression-free survival (PFS)

    Day 1 to date of death (OS) or relapse/death (PFS) or last follow up, whichever comes first Overall survival (OS) and progression-free survival (PFS) will be assessed using the Kaplan-Meier product-limit method, with the median and 95% CI estimated.

    Time frame: Up to 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Jun 2028, 28 months after the start.

Of 128 non-industry observational studies under Leukemia, Myeloid, Acute, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 234. This study's planned 28 months is below that.

Counting every sponsor, half of 160 studies reached it within 54 months; a quarter within 35 and three quarters within 154.

Primary completion moved once since we started tracking on Sep 25, 2026: Dec 2027 → Jun 2028, on Oct 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2026
First posted
May 29, 2026
StartActual
Jan 28, 2026
Primary completionEst.
Jun 22, 2028was Dec 2027
CompletionEst.
Jun 22, 2028
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 31, 2027→Jun 22, 2028
Oct 6, 2026
Study completion
Jun 1, 2028→Jun 22, 2028
Oct 6, 2026
Enrollment
18→20
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Primary completion Dec 31, 2027→Jun 22, 2028
    Study completion Jun 1, 2028→Jun 22, 2028
    Enrollment 18→20
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07613385
Responsible party
Sponsor
First posted
May 29, 2026
Start date
Jan 28, 2026
Primary completion
Jun 22, 2028 (estimated)
Completion
Jun 22, 2028 (estimated)
Last update
Oct 6, 2026

Study contacts

Pamela Becker, MD
Contact
pbecker@coh.org
626-218-2405
Pamela Becker, MD
principal investigator · City of Hope Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion